Charles Swanton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4454222/publications.pdf

Version: 2024-02-01

293 papers	67,802 citations	1992 101 h-index	834 245 g-index
332 all docs	332 docs citations	332 times ranked	83166 citing authors

#	Article	IF	Citations
1	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	9.6	21
2	Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. Lancet, The, 2022, 399, 800-802.	13.7	35
3	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet, The, 2022, 399, 905-907.	13.7	60
4	Three-dose vaccination elicits neutralising antibodies against omicron. Lancet, The, 2022, 399, 715-717.	13.7	82
5	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell, 2022, 40, 114-116.	16.8	50
6	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery, 2022, 12, 654-669.	9.4	34
7	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	7.8	30
8	Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities. Cancer Research, 2022, 82, 1589-1602.	0.9	7
9	The translational challenges of precision oncology. Cancer Cell, 2022, 40, 458-478.	16.8	38
10	A local human VÎ´1 T cell population is associated with survival in nonsmall-cell lung cancer. Nature Cancer, 2022, 3, 696-709.	13.2	39
11	CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. Science Translational Medicine, 2022, 14, .	12.4	8
12	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature Biotechnology, 2022, 40, 1624-1633.	17.5	31
13	Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. Epilepsy and Behavior, 2021, 115, 107602.	1.7	11
14	Consequences of COVID-19 for cancer care â€" a CRUK perspective. Nature Reviews Clinical Oncology, 2021, 18, 3-4.	27.6	65
15	A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms. Mutagenesis, 2021, 36, 75-86.	2.6	19
16	Understanding the impact of immune-mediated selection on lung cancer evolution. British Journal of Cancer, 2021, 124, 1615-1617.	6.4	5
17	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell, 2021, 184, 596-614.e14.	28.9	485
18	A Functional Taxonomy of Tumor Suppression in Oncogenic KRASâ€"Driven Lung Cancer. Cancer Discovery, 2021, 11, 1754-1773.	9.4	35

#	Article	IF	Citations
19	Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nature Communications, 2021, 12, 1751.	12.8	66
20	Tracking Cancer Evolution through the Disease Course. Cancer Discovery, 2021, 11, 916-932.	9.4	77
21	AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature, 2021, 592, 799-803.	27.8	78
22	Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell, 2021, 184, 2239-2254.e39.	28.9	260
23	Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution, 2021, 5, 1033-1045.	7.8	50
24	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research, 2021, 27, 4311-4324.	7.0	44
25	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nature Medicine, 2021, 27, 1362-1366.	30.7	70
26	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. Cancer Discovery, 2021, 11, 2456-2473.	9.4	74
27	Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet, The, 2021, 397, 2331-2333.	13.7	490
28	E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. Oncogene, 2021, 40, 5567-5578.	5.9	3
29	Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. ELife, 2021, 10, .	6.0	42
30	AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet, The, 2021, 398, 207-209.	13.7	112
31	Capturing cancer evolution using genetically engineered mouse models (GEMMs). Trends in Cell Biology, 2021, 31, 1007-1018.	7.9	20
32	Cancer evolution: Darwin and beyond. EMBO Journal, 2021, 40, e108389.	7.8	118
33	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	10.7	178
34	Using DNA sequencing data to quantify T cell fraction and therapy response. Nature, 2021, 597, 555-560.	27.8	36
35	Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet, The, 2021, 398, 1038-1041.	13.7	73
36	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications, 2021, 12, 5606.	12.8	76

#	Article	IF	Citations
37	Immunogenomics of Colorectal Cancer Response to CheckpointÂBlockade: Analysis of the KEYNOTE 177 Trial andÂValidation Cohorts. Gastroenterology, 2021, 161, 1179-1193.	1.3	62
38	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	1.1	274
39	Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biology, 2021, 11, 200247.	3.6	28
40	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	9.4	139
41	Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nature Communications, 2021, 12, 5906.	12.8	36
42	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	13.2	66
43	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	13.2	123
44	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	16.8	126
45	Intratumor heterogeneity reflects clinical disease course. Nature Cancer, 2020, 1, 3-6.	13.2	44
46	Scientific consensus on the COVID-19 pandemic: we need to act now. Lancet, The, 2020, 396, e71-e72.	13.7	189
47	The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, 2020, 583, 807-812.	27.8	96
48	Cancer Research: The Lessons to Learn from COVID-19. Cancer Discovery, 2020, 10, 1263-1266.	9.4	25
49	Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. Cancer Discovery, 2020, 10, 1489-1499.	9.4	60
50	Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncology, The, 2020, 21, 1035-1044.	10.7	359
51	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications, 2020, 11, 3800.	12.8	61
52	Pervasive chromosomal instability and karyotype order in tumour evolution. Nature, 2020, 587, 126-132.	27.8	221
53	MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nature Communications, 2020, 11, 4527.	12.8	32
54	Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science, 2020, 370, 1339-1343.	12.6	735

#	Article	IF	Citations
55	Genomic landscape of platinum resistant and sensitive testicular cancers. Nature Communications, 2020, 11, 2189.	12.8	43
56	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 2020, 26, 1054-1062.	30.7	181
57	Protecting â€œcovid protectedâ€•cancer hubs. BMJ, The, 2020, 369, m2062.	6.0	4
58	Scalable and robust SARS-CoV-2 testing in an academic center. Nature Biotechnology, 2020, 38, 927-931.	17.5	32
59	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
60	Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nature Genetics, 2020, 52, 283-293.	21.4	168
61	Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. Lancet, The, 2020, 396, e6-e7.	13.7	196
62	Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Reports, 2020, 30, 481-496.e6.	6.4	111
63	Securing the future of the clinician-scientist. Nature Cancer, 2020, 1, 139-141.	13.2	20
64	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology, 2020, 31, 745-759.	1.2	770
65	COVID-19: the case for health-care worker screening to prevent hospital transmission. Lancet, The, 2020, 395, 1418-1420.	13.7	368
66	Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. Nature Communications, 2020, 11, 1792.	12.8	25
67	Take lessons from cancer evolution to the clinic. Nature, 2020, 581, 382-383.	27.8	19
68	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nature Cancer, 2020, 1, 546-561.	13.2	74
69	Neoantigen quality, not quantity. Science Translational Medicine, 2019, 11, .	12.4	98
70	UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell, 2019, 179, 219-235.e21.	28.9	270
71	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
72	Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine, 2019, 25, 1549-1559.	30.7	147

#	Article	IF	Citations
73	Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Medicine, 2019, 25, 1534-1539.	30.7	146
74	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	30.7	75
75	Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nature Medicine, 2019, 25, 517-525.	30.7	178
76	Neoantigen-directed immune escape in lung cancer evolution. Nature, 2019, 567, 479-485.	27.8	639
77	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2019, 20, 518-530.	10.7	362
78	Resolving genetic heterogeneity in cancer. Nature Reviews Genetics, 2019, 20, 404-416.	16.3	443
79	Artificial intelligence in cancer imaging: Clinical challenges and applications. Ca-A Cancer Journal for Clinicians, 2019, 69, 127-157.	329.8	965
80	Prospective analysis of 895 patients on a UK Genomics Review Board. ESMO Open, 2019, 4, e000469.	4.5	22
81	An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood. Methods in Molecular Biology, 2019, 1884, 15-42.	0.9	15
82	The function and dysfunction of memory <scp>CD</scp>8⁺ T cells in tumor immunity. Immunological Reviews, 2018, 283, 194-212.	6.0	121
83	Expansion of airway basal epithelial cells from primary human nonâ€small cell lung cancer tumors. International Journal of Cancer, 2018, 143, 160-166.	5.1	18
84	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	16.8	827
85	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell, 2018, 173, 611-623.e17.	28.9	398
86	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, 2018, 173, 595-610.e11.	28.9	472
87	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, 2018, 173, 581-594.e12.	28.9	609
88	Chromosomal instability drives metastasis through a cytosolic DNA response. Nature, 2018, 553, 467-472.	27.8	1,002
89	Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Annals of Oncology, 2018, 29, 271-279.	1.2	106
90	Cancer therapeutics through an evolutionary lens. Journal of the Royal Society of Medicine, 2018, 111, 8-14.	2.0	8

#	Article	IF	Citations
91	Determinants and clinical implications of chromosomal instability in cancer. Nature Reviews Clinical Oncology, 2018, 15, 139-150.	27.6	272
92	The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Annals of Oncology, 2018, 29, 30-35.	1.2	118
93	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell, 2018, 33, 649-663.e4.	16.8	448
94	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	1.6	1
95	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology, 2018, 36, 536-542.	1.6	362
96	Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. Journal of Experimental Medicine, 2018, 215, 2748-2759.	8.5	34
97	Kidney cancer: The next decade. Journal of Experimental Medicine, 2018, 215, 2477-2479.	8.5	125
98	Early stage NSCLC â€" challenges to implementing ctDNA-based screening and MRD detection. Nature Reviews Clinical Oncology, 2018, 15, 577-586.	27.6	281
99	Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nature Communications, 2018, 9, 3070.	12.8	64
100	BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. Cancer Cell, 2017, 31, 79-93.	16.8	83
101	APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability. Cancer Discovery, 2017, 7, 218-233.	9.4	87
102	Renal cell carcinoma. Nature Reviews Disease Primers, 2017, 3, 17009.	30.5	1,727
103	Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell, 2017, 168, 613-628.	28.9	1,957
104	Evolutionary dynamics in pre-invasive neoplasia. Current Opinion in Systems Biology, 2017, 2, 1-8.	2.6	12
105	Constraints in cancer evolution. Biochemical Society Transactions, 2017, 45, 1-13.	3.4	29
106	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	21.4	112
107	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	14.3	323
108	Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Annals of Oncology, 2017, 28, 1448-1456.	1.2	283

#	Article	IF	Citations
109	The future of UK healthcare: problems and potential solutions to a system in crisis. Annals of Oncology, 2017, 28, 1751-1755.	1.2	25
110	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	27.8	1,287
111	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	27.0	1,786
112	Implications of cancer evolution for drug development. Nature Reviews Drug Discovery, 2017, 16, 441-442.	46.4	28
113	Evolving adoptive cellular therapies in urological malignancies. Lancet Oncology, The, 2017, 18, e341-e353.	10.7	22
114	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro-Oncology, 2017, 19, 1058-1067.	1.2	38
115	Cellular Prion Protein PrPC and Ecto-5â€²-Nucleotidase Are Markers of the Cellular Stress Response to Aneuploidy. Cancer Research, 2017, 77, 2914-2926.	0.9	7
116	Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026617.	6.2	59
117	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	28.9	968
118	Cancer Evolution Constrained by the Immune Microenvironment. Cell, 2017, 170, 825-827.	28.9	60
119	Classifying the evolutionary and ecological features of neoplasms. Nature Reviews Cancer, 2017, 17, 605-619.	28.4	303
120	Tumor Evolution as a Therapeutic Target. Cancer Discovery, 2017, 7, 805-817.	9.4	158
121	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Annals of Oncology, 2017, 28, 2472-2480.	1.2	45
122	The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. Cancer Discovery, 2017, 7, 796-798.	9.4	14
123	Origins of lymphatic and distant metastases in human colorectal cancer. Science, 2017, 357, 55-60.	12.6	358
124	Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nature Communications, 2017, 8, 1773.	12.8	54
125	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 2017, 49, 1693-1704.	21.4	423
126	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncology, The, 2017, 18, 1009-1021.	10.7	716

#	Article	IF	Citations
127	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. Annual Review of Cancer Biology, 2017, 1, 223-240.	4.5	20
128	The Role of Aneuploidy in Cancer Evolution. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a028373.	6.2	189
129	Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene, 2017, 36, 746-755.	5.9	98
130	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	1.9	62
131	Cyclin D mediates tolerance of genome-doubling in cancers with functional p53. Annals of Oncology, 2017, 28, 149-156.	1.2	43
132	The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Medicine, 2017, 15, 133.	5.5	166
133	Quantification of tumour evolution and heterogeneity via Bayesian epiallele detection. BMC Bioinformatics, 2017, 18, 354.	2.6	15
134	Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 402-402.	1.6	49
135	Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e141-e149.	3.8	63
136	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Medicine, 2016, 13, e1002136.	8.4	28
137	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 2016, 27, 1443-1448.	1.2	79
138	Metastasis as an evolutionary process. Science, 2016, 352, 169-175.	12.6	497
139	Re-Evaluating Clonal Dominance in Cancer Evolution. Trends in Cancer, 2016, 2, 263-276.	7.4	39
140	International cancer seminars: a focus on kidney cancer. Annals of Oncology, 2016, 27, 1382-1385.	1.2	18
141	Clinical Implications of Genomic Discoveries in Lung Cancer. New England Journal of Medicine, 2016, 374, 1864-1873.	27.0	235
142	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nature Biotechnology, 2016, 34, 1037-1045.	17.5	279
143	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011.	13.7	132
144	DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biology, 2016, 17, 185.	8.8	140

#	Article	IF	Citations
145	deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biology, 2016, 17, 31.	8.8	917
146	A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biology, 2016, 17, 99.	8.8	150
147	Environmental emissions, public health and lung cancer risk. Annals of Oncology, 2016, 27, 211-212.	1.2	9
148	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
149	RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress. Oncogene, 2016, 35, 4009-4019.	5.9	37
150	Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy. Cancer Discovery, 2016, 6, 122-124.	9.4	13
151	Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Annals of Oncology, 2016, 27, 862-867.	1.2	137
152	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	12.6	2,445
153	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program â€œCASCADEâ€• PLoS Medicine, 2016, 13, e1002204.	8.4	119
154	Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e141-e149.	3.8	49
155	TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. BMC Medical Genomics, 2015, 8, 58.	1.5	49
156	SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene, 2015, 34, 5699-5708.	5.9	147
157	How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. Current Opinion in Urology, 2015, 25, 358-366.	1.8	34
158	Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in ALK-Rearranged Lung Adenocarcinoma?. Journal of Clinical Oncology, 2015, 33, 3681-3683.	1.6	9
159	SnapShot: Renal Cell Carcinoma. Cell, 2015, 163, 1556-1556.e1.	28.9	50
160	Tetraploidy and CIN: a dangerous combination. Cell Cycle, 2015, 14, 3217-3217.	2.6	6
161	Cancer Evolution Constrained by Mutation Order. New England Journal of Medicine, 2015, 372, 661-663.	27.0	22
162	Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution. Cancer Cell, 2015, 27, 15-26.	16.8	923

#	Article	IF	Citations
163	Can oncology recapitulate paleontology? Lessons from species extinctions. Nature Reviews Clinical Oncology, 2015, 12, 273-285.	27.6	31
164	Translational Implications of Tumor Heterogeneity. Clinical Cancer Research, 2015, 21, 1258-1266.	7.0	424
165	Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853.	30.7	604
166	Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy. Cancer Discovery, 2015, 5, 821-831.	9.4	227
167	Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Annals of Oncology, 2015, 26, 1340-1346.	1.2	61
168	Analysis of intratumor heterogeneity unravels lung cancer evolution. Molecular and Cellular Oncology, 2015, 2, e985549.	0.7	28
169	Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. Annals of Oncology, 2015, 26, 880-887.	1.2	37
170	APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discovery, 2015, 5, 704-712.	9.4	392
171	Clinical management of breast cancer heterogeneity. Nature Reviews Clinical Oncology, 2015, 12, 381-394.	27.6	400
172	Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Science Translational Medicine, 2015, 7, 283ra54.	12.4	589
173	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature Communications, 2015, 6, 6336.	12.8	100
174	Inferring mutational timing and reconstructing tumour evolutionary histories. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 264-275.	7.4	48
175	New approaches for improving outcomes in breast cancer in Europe. Breast, 2015, 24, 321-330.	2.2	42
176	The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Annals of Oncology, 2015, 26, 2464-2469.	1.2	58
177	Tracking tumour evolution through liquid biopsy. Nature Reviews Clinical Oncology, 2015, 12, 565-566.	27.6	4
178	Relapse models for clear cell renal carcinoma. Lancet Oncology, The, 2015, 16, e376-e378.	10.7	3
179	Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. European Urology, 2015, 67, 729-737.	1.9	100
180	The Genome of the Chicken DT40 Bursal Lymphoma Cell Line. G3: Genes, Genomes, Genetics, 2014, 4, 2231-2240.	1.8	25

#	Article	IF	Citations
181	89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients. Clinical Cancer Research, 2014, 20, 3945-3954.	7.0	105
182	Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. Cancer Research, 2014, 74, 2946-2961.	0.9	20
183	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biology, 2014, 12, e1001906.	5.6	185
184	Multidisciplinary urological engagement in translational renal cancer research. BJU International, 2014, 114, 474-475.	2.5	2
185	Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution. Cancer Discovery, 2014, 4, 175-185.	9.4	359
186	Prioritizing targets for precision cancer medicine. Annals of Oncology, 2014, 25, 2295-2303.	1.2	146
187	Epigenetic Noise Fuels Cancer Evolution. Cancer Cell, 2014, 26, 775-776.	16.8	12
188	Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biology, 2014, 15, 433.	8.8	69
189	Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. Genome Biology, 2014, 15, 470.	8.8	11
190	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. European Urology, 2014, 66, 936-948.	1.9	141
191	Chromosomal Instability Selects Gene Copy-Number Variants Encoding Core Regulators of Proliferation in ER+ Breast Cancer. Cancer Research, 2014, 74, 4853-4863.	0.9	66
192	Spatial and temporal cancer evolution: causes and consequences of tumour diversity. Clinical Medicine, 2014, 14, s33-s37.	1.9	23
193	Chromosomal Instability, Aneuploidy, and Cancer. Frontiers in Oncology, 2014, 4, 161.	2.8	23
194	Cancer evolution: the final frontier of precision medicine?. Annals of Oncology, 2014, 25, 549-551.	1.2	31
195	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics, 2014, 46, 225-233.	21.4	1,103
196	Implications of intratumour heterogeneity for treatment stratification. Journal of Pathology, 2014, 232, 264-273.	4.5	53
197	Ccdc13; a novel human centriolar satellite protein required for ciliogenesis and genome stability. Journal of Cell Science, 2014, 127, 2910-9.	2.0	35
198	The evolution of the unstable cancer genome. Current Opinion in Genetics and Development, 2014, 24, 61-67.	3.3	62

#	Article	IF	Citations
199	Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer. Breast Cancer Research and Treatment, 2014, 148, 221-229.	2.5	10
200	Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biology, 2014, 15, 453.	8.8	180
201	Combined inhibition of BRAF and MEK in melanoma patients. Lancet Oncology, The, 2014, 15, 908-910.	10.7	6
202	Cancer: Evolution Within a Lifetime. Annual Review of Genetics, 2014, 48, 215-236.	7.6	196
203	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science, 2014, 346, 251-256.	12.6	962
204	Tumour heterogeneity and the evolution of polyclonal drug resistance. Molecular Oncology, 2014, 8, 1095-1111.	4.6	347
205	SAFIR01: steps towards precision treatment in breast cancer. Lancet Oncology, The, 2014, 15, 242-243.	10.7	8
206	Response to Bakhoum et al.. Current Biology, 2014, 24, R150.	3.9	2
207	HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis. Nature, 2013, 502, 381-384.	27.8	94
208	Computational optimisation of targeted DNA sequencing for cancer detection. Scientific Reports, 2013, 3, 3309.	3.3	20
209	The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 2013, 501, 338-345.	27.8	1,969
210	A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Research, 2013, 15, R110.	5.0	86
211	Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Medicine, 2013, 5, 101.	8.2	38
212	Cancer heterogeneity and â€œThe Struggle for Existenceâ€• Diagnostic and analytical challenges. Cancer Letters, 2013, 340, 220-226.	7.2	26
213	Plasma-Derived Tumor DNA Analysis at Whole-Genome Resolution. Clinical Chemistry, 2013, 59, 6-8.	3.2	6
214	Modelling the evolution of genetic instability during tumour progression. Evolutionary Applications, 2013, 6, 20-33.	3.1	41
215	<scp>LRIG1</scp> regulates cadherinâ€dependent contact inhibition directing epithelial homeostasis and preâ€invasive squamous cell carcinoma development. Journal of Pathology, 2013, 229, 608-620.	4.5	34
216	A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. Breast Cancer Research and Treatment, 2013, 138, 691-698.	2.5	6

#	Article	IF	Citations
217	Taxane benefit in breast cancerâ€"a role for grade and chromosomal stability. Nature Reviews Clinical Oncology, 2013, 10, 357-364.	27.6	48
218	Replication stress links structural and numerical cancer chromosomal instability. Nature, 2013, 494, 492-496.	27.8	694
219	Adapting Clinical Paradigms to the Challenges of Cancer Clonal Evolution. American Journal of Pathology, 2013, 182, 1962-1971.	3.8	40
220	Parallel evolution of tumour subclones mimics diversity between tumours. Journal of Pathology, 2013, 230, 356-364.	4.5	79
221	Cancer heterogeneity: implications for targeted therapeutics. British Journal of Cancer, 2013, 108, 479-485.	6.4	753
222	Tumour heterogeneity and immune-modulation. Current Opinion in Pharmacology, 2013, 13, 497-503.	3.5	37
223	Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Annals of Oncology, 2013, 24, 647-654.	1.2	117
224	Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2013, 31, 971-972.	1.6	6
225	Ultraâ€deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. Journal of Pathology, 2013, 231, 424-432.	4.5	93
226	Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 127-134.	3.8	28
227	Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 127-134.	3.8	13
228	The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer. PLoS ONE, 2013, 8, e56707.	2.5	28
229	The centriolar satellite protein Cep131 is important for genome stability. Development (Cambridge), 2013, 140, e207-e207.	2.5	0
230	Intratumor Heterogeneity: Seeing the Wood for the Trees. Science Translational Medicine, 2012, 4, 127ps10.	12.4	443
231	The centriolar satellite protein Cep131 is important for genome stability.. Journal of Cell Science, 2012, 125, 4770-9.	2.0	92
232	Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?. Frontiers in Oncology, 2012, 2, 49.	2.8	22
233	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA Journal, 2012, 3, 1.	6.1	18
234	Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. EPMA Journal, 2012, 3, 3.	6.1	23

#	Article	IF	Citations
235	Intratumor Heterogeneity: Evolution through Space and Time. Cancer Research, 2012, 72, 4875-4882.	0.9	844
236	Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. Journal of Hepatology, 2012, 56, 877-885.	3.7	43
237	Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. EPMA Journal, 2012, 3, 6.	6.1	2
238	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
239	CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploidâ€specific cancer cell death through autophagy induction. Journal of Pathology, 2012, 226, 482-494.	4.5	48
240	A wholeâ€genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptorâ€negative and â€positive breast cancers. Journal of Pathology, 2012, 227, 29-41.	4.5	58
241	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New England Journal of Medicine, 2012, 366, 883-892.	27.0	6,769
242	Genomeâ€wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. Journal of Pathology, 2012, 227, 146-156.	4.5	92
243	Epigenetic regulation in RCC: opportunities for therapeutic intervention?. Nature Reviews Urology, 2012, 9, 147-155.	3.8	51
244	Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Reports, 2012, 13, 528-538.	4.5	332
245	Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics. Biochemical Pharmacology, 2012, 83, 1013-1020.	4.4	59
246	Recent Developments in Treatment Stratification for Metastatic Breast Cancer. Drugs, 2011, 71, 2099-2113.	10.9	12
247	KRAS 3â€²-UTR variants and stratification of breast-cancer risk. Lancet Oncology, The, 2011, 12, 318-319.	10.7	5
248	Breast cancer genome heterogeneity: a challenge to personalised medicine?. Breast Cancer Research, 2011, 13, 104.	5.0	46
249	Promoting predictive, preventive and personalised medicine: European event of global importance. EPMA Journal, 2011, 2, 131-136.	6.1	9
250	Chromosomal Instability Confers Intrinsic Multidrug Resistance. Cancer Research, 2011, 71, 1858-1870.	0.9	391
251	Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer. Cancer Research, 2011, 71, 3447-3452.	0.9	296
252	Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer. Oncologist, 2011, 16, 1535-1546.	3.7	50

#	Article	IF	Citations
253	Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Review of Anticancer Therapy, 2011, 11, 639-649.	2.4	14
254	Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2183-2194.	2.5	141
255	A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget, 2011, 2, 529-537.	1.8	8
256	Chemotherapy and metastatic breast cancer. , 2011, , 67-92.		0
257	Targeting chromosomal instability and tumour heterogeneity in HER2â€positive breast cancer. Journal of Cellular Biochemistry, 2010, 111, 782-790.	2.6	44
258	A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. British Journal of Cancer, 2010, 103, 607-612.	6.4	11
259	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer, 2010, 103, 1139-1143.	6.4	381
260	From genomic landscapes to personalized cancer managementâ€”is there a roadmap?. Annals of the New York Academy of Sciences, 2010, 1210, 34-44.	3.8	16
261	FKBPL Regulates Estrogen Receptor Signaling and Determines Response to Endocrine Therapy. Cancer Research, 2010, 70, 1090-1100.	0.9	38
262	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. Current Cancer Drug Targets, 2010, 10, 799-812.	1.6	28
263	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. Oncologist, 2010, 15, 390-404.	3.7	155
264	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer, 2010, 46, 2166-2177.	2.8	71
265	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncology, The, 2010, 11, 358-365.	10.7	116
266	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine, 2010, 2, 53.	8.2	43
267	Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER Status. PLoS ONE, 2010, 5, e15031.	2.5	26
268	Molecular classification of solid tumours: towards pathway-driven therapeutics. British Journal of Cancer, 2009, 100, 1517-1522.	6.4	68
269	Review: Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2009, 1, 15-27.	3.2	8
270	Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy. Cell Cycle, 2009, 8, 3262-3266.	2.6	101

#	Article	IF	Citations
271	RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. Expert Reviews in Molecular Medicine, 2009, 11, e15.	3.9	6
272	Chromosomal instability determines taxane response. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8671-8676.	7.1	244
273	Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer, 2009, 9, 489-499.	28.4	602
274	Unraveling the Complexity of Endocrine Resistance in Breast Cancer by Functional Genomics. Cancer Cell, 2008, 13, 83-85.	16.8	12
275	Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Research, 2008, 10, 214.	5.0	20
276	Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure. Cell Cycle, 2008, 7, 3947-3948.	2.6	3
277	Targeting Polo-Like Kinase: Learning Too Little Too Late?. Journal of Clinical Oncology, 2008, 26, 5497-5499.	1.6	17
278	Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. Expert Opinion on Investigational Drugs, 2008, 17, 523-546.	4.1	31
279	Initiation of High Frequency Multi-Drug Resistance Following Kinase Targeting by siRNAs. Cell Cycle, 2007, 6, 2001-2004.	2.6	14
280	Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs. Cancer Cell, 2007, 11, 498-512.	16.8	351
281	The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel. Cancer Cell, 2007, 12, 514-527.	16.8	202
282	Principles of Targeted and Biological Therapies. , 2006, , 73-90.		0
283	Anthracycline cardiotoxicity. Expert Opinion on Drug Safety, 2006, 5, 791-809.	2.4	108
284	Chromosomal Instability, Colorectal Cancer and Taxane Resistance. Cell Cycle, 2006, 5, 818-823.	2.6	73
285	Her2-Targeted Therapies in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 4377s-4383s.	7.0	63
286	Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta OncolÃ³gica, 2006, 45, 196-201.	1.8	131
287	Cell-cycle targeted therapies. Lancet Oncology, The, 2004, 5, 27-36.	10.7	230
288	RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?. Lancet Oncology, The, 2004, 5, 653-654.	10.7	11

#	Article	IF	Citations
289	Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products. International Journal of Experimental Pathology, 2001, 82, 3-13.	1.3	42
290	Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO Journal, 1999, 18, 654-663.	7.8	141
291	Overcoming inhibitions: subversion of CKI function by viral cyclins. Trends in Biochemical Sciences, 1999, 24, 116-120.	7.5	24
292	Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature, 1997, 390, 184-187.	27.8	338
293	APOBEC3 as a driver of genetic intratumor heterogeneity. Molecular and Cellular Oncology, 0, , .	0.7	0